Skip to main content
. Author manuscript; available in PMC: 2019 Jul 11.
Published in final edited form as: JAMA Oncol. 2015 Nov;1(8):1087–1095. doi: 10.1001/jamaoncol.2015.2736

Figure 1.

Figure 1.

CONSORT diagram. Fifty-one patients screened, 48 were eligible and randomized. Twenty-five randomized to Arm A; 23 to Arm B. All patients on Arm A (25) and Arm B (23) were evaluable for the primary endpoint.